Cutera Inc To Release AviClear in the UK
Cutera Inc., a leading provider of aesthetic and dermatology solutions, today announces a limited commercial release of AviClear for the UK & Ireland markets. This highly anticipated launch follows the successful rollout in the US and Canada.
“We are excited to be offering this ground-breaking AviClear treatment to physicians and patients in the UK & Ireland”, said Sam Keene, Regional Leader UK & Ireland at Cutera. “Based on feedback from our early adopters, we are confident that patient demand and clinic installations will continue to grow over the next few months and that the affordability, efficacy, and durability of AviClear will establish it as the gold standard of care for acne sufferers.”
IMCAS Expert Panel Symposium
Cutera is hosting an AviClear symposium at IMCAS (1-3 Feb, 2024), with a global panel of leading key opinion leaders discussing AviClear clinical data and in-practice outcomes. Moderated by Dr David Goldberg and supported by Dr Tapan Patel, the panel will outline the trial results underpinning the FDA clearances, alongside their own in-clinic experiences. The Symposium will take place at:
Industry Symposium: The Future of Acne Treatment with AviClear: An In-Depth Panel Discussion on Clinical Outcomes with the 1726 nm Laser with panelists Dr David Goldberg, Dr Vivian Bucay, Dr Jessica Weiser, Dr Tapan Patel, Dr Arash Moradzadeh at 1 February 2024, 13:30 to 14:30 - Room 352 - Level
The AviClear Difference
As the first FDA-cleared laser treatment for long-term inflammatory acne, AviClear represents a next-generation treatment option for UK practitioners, significantly eliminating acne in just three 30-minute treatment sessions.
Results from the pivotal clinical trials showed that: * **
• 92% of patients treated with AviClear saw at least half of their acne resolved at 12 months after the final treatment session.
• 2 out of 3 patients were assessed as clear or almost-clear 12 months after their final treatment session.
• 93% of patients showed a +1 IGA improvement score at 12 months after the final treatment session.
• 9/10 of patients were “satisfied” or “very satisfied” after treatment.
References